Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Gonna be a multi billion dollar company soon imo get on board

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

Gonna be a multi billion dollar company soon imo get on board

rvxrocks

Feb 01, 2022 07:46PM

Re: Gonna be a multi billion dollar company soon imo get on board

LongRVXer

Feb 01, 2022 09:04PM

Re: Gonna be a multi billion dollar company soon imo get on board

rvxrocks

Feb 01, 2022 10:05PM

Re: Gonna be a multi billion dollar company soon imo get on board

Buckeyes

Feb 02, 2022 03:19AM

10-41

Rank: President [?]

Points: 1511 [?]

Votes: 12 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gonna be a multi billion dollar company soon imo get on board

in response to

Re: Gonna be a multi billion dollar company soon imo get on board

Buckeyes

posted on Feb 02, 2022 02:05PM

So, with the interviewers/media suddenly discovering Resverlogix and the field of epigenetics, wouldn't it be a way more more powerful punch to also include Zenith Epigenetics in on the discussion?

Pretty impressive what they're doing there! Too bad they couldn't do better than the latest addition to the Zenith BOD. Very frustrating! They manage to create these impressive clinical steering committees on the Resverlogix side, and then stay the course with these old folks! I say we get some newer and more dynamic BOD blood into the mix in both Resverlogix and Zenith!

Clinical Update on Zenith Epigenetics, for those who missed the news release from a few days ago:

Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Our lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials:

	1. Phase 2b metastatic castration resistant prostate (mCRPC) cancer trial in combination with androgen receptor inhibitor, XTANDI (enzalutamide):
	Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC Conducted in collaboration Astellas Pharma and Newsoara Biopharma This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors Study rationale and trial design will be presented at the upcoming ASCO Genitourinary Cancers Symposium (February 17-19, 2022)
	2. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib):
	Conducted in collaboration with Pfizer and Newsoara Biopharma This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval Results from the completed Phase 2 portion of the trial are expected to be presented at the ASCO Annual Meeting (June 3-7, 2022)
	3. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI:
	Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan Data to date shows that the combination can be dosed safely and is clinically active The trial has progressed to the efficacy stage and is accruing well
	4. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab:
	National Cancer Institute is conducting this trial in collaboration with Zenith and BMS This is a second trial combining immune-checkpoint inhibitors with ZEN-3694 Expected to enroll first patient in the first quarter of 2022
	5. Phase 1b/2 NUT carcinoma trial in combination with chemotherapy:
	Conducted in collaboration with the National Cancer Institute Ultra-orphan indication with significant unmet need Expected to enroll first patient in the first half of 2022
	6. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat:
	National Cancer Institute is conducting this trial in collaboration with Zenith and Syndax Expected to enroll first patient in the first half of 2022